Inclusion Criteria:

          -  Aged 18 years or older

          -  Confirmed diagnosis of select advanced malignancy

          -  Parts 1 and 2:

               -  Unresponsive to currently available therapy and there is no standard-of-care
                  therapy available in the judgment of the investigator.

               -  Not currently a candidate for curative treatment

          -  Parts 3 and 4:

               -  Subjects with relapsed/refractory AML must have received either induction
                  chemotherapy for AML or hypomethylating agents for hematologic disease before
                  AML.

               -  Elderly subjects (≥ 65 years) with newly diagnosed AML must be treatment naive
                  and unfit for intensive chemotherapy.

               -  Myelofibrosis subjects must have been treated with ruxolitinib for ≥ 6 months
                  with a stable dose for ≥ 8 weeks (acceptable doses are 5 mg twice daily [BID] to
                  25 mg BID).

          -  Willingness to undergo a pretreatment bone marrow biopsy and/or aspirate, or archival
             sample obtained since completion of most recent therapy (as appropriate to subjects
             with existing bone marrow disease or for whom bone marrow examination is a component
             of disease status assessment)

          -  Eastern Cooperative Oncology Group (ECOG) performance status

               -  Part 1: 0 or 1

               -  Parts 2, 3 and 4: 0, 1, or 2

          -  Life expectancy > 12 weeks or ≥ 24 weeks for Part 3 and Part 4 MF subjects.

        Exclusion Criteria:

          -  Inadequate bone marrow or organ function

          -  Received an investigational agent within 5 half-lives or 14 days, whichever is longer,
             prior to receiving the first dose of study drug

          -  Received non-biologic anticancer medication within 5 half-lives prior to receiving the
             first dose of study drug (within 6 weeks for mitomycin-C or nitrosoureas), within 28
             days for any antibodies or biological therapies

          -  Prior receipt of a PIM inhibitor

          -  Any history of disease involving the central nervous system (Part 1). Known active
             disease involving the central nervous system (Part 2).

          -  Screening corrected QT interval (QTc) interval > 470 milliseconds

          -  Radiotherapy within the 2 weeks prior to initiation of treatment

          -  Chronic or current active infection requiring systemic antibiotic, antifungal, or
             antiviral treatment